Skinvisible, Inc., the developers of Invisicare, a patented polymer delivery system that provides life cycle management for topical products, and RHEI Pharmaceuticals NV, a Belgium-based pharmaceutical company that in-licenses drugs for sale in China, announced they have signed a first option agreement.

The agreement gives RHEI the first option to license the exclusive rights for Skinvisible's dermatology products for the territory of China, Hong Kong and Taiwan. Specifically the agreement is for over-the-counter and prescription dermatology products formulated with Invisicare that have been approved in a reference country. Terms of the agreement were not disclosed.

As part of the agreement, RHEI will augment its existing product lines by seeking approval and then marketing and manufacturing Skinvisible's Invisicare dermatology products in the approved territory.